Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$16.04 USD
-0.08 (-0.50%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $16.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ROIV 16.04 -0.08(-0.50%)
Will ROIV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice
Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Other News for ROIV
Is ROIV showing downside potential? MACD Bearish Signal Line Cross shows up after sinking 0.5%
ROIV rises 0.56% on October 9, leaving the technical picture intact
ROIV falls 0.56% on October 8, leaving the technical picture intact
Slingshot Bullish appears for ROIV after 0.86% move
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV)